Przejdź do zawartości

Onkologia

Leczenie niedokrwistości

Środki stymulujące erytropoezę

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (opens new window)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Źródło‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (opens new window)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (opens new window)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Źródło‎: Acta Haematol 2007;117(3):162-7.

Indeks‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (opens new window)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (opens new window)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Źródło‎: Am J Hematol 2013;88(12):990-6.

Indeks‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (opens new window)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (opens new window)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Źródło‎: J Clin Oncol 2011;29(28):3791-7.

Indeks‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (opens new window)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (opens new window)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Źródło‎: Cancer 2012;118(3):848-55.

Indeks‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (opens new window)

Management of anemia in cancer patients. (opens new window)

Calabrich A, Katz A.

Źródło‎: Future Oncol 2011;7(4):507-17.

Indeks‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (opens new window)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (opens new window)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Źródło‎: BJU Int 2011;108(10):1582-7.

Indeks‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (opens new window)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (opens new window)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Źródło‎: J Clin Oncol 2010;28(13):2239-45.

Indeks‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (opens new window)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (opens new window)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Źródło‎: Br J Cancer 2011;105(9):1267-72.

Indeks‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (opens new window)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (opens new window)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Źródło‎: J Intern Med 2017;281(3):284-99.

Indeks‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (opens new window)

How I treat cancer-associated anemia. (opens new window)

Gilreath JA, Rodgers GM

Źródło‎: Blood 2020;136(7):801-13.

Indeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (opens new window)

Update on safety of ESAs in cancer-induced anemia. (opens new window)

Glaspy J.

Źródło‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Indeks‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (opens new window)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (opens new window)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Źródło‎: Eur J Haematol. 2023 110(4):354-61.

Indeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (opens new window)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (opens new window)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Źródło‎: Int J Hematol 2015;102(4):401-12.

Indeks‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (opens new window)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opens new window)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Źródło‎: Cancer 2013;119(1):107-14.

Indeks‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opens new window)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (opens new window)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Źródło‎: J Natl Cancer Inst 2013;105(14):1018-26.

Indeks‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (opens new window)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (opens new window)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Źródło‎: Cancer Sci 2013;104(4):481-5.

Indeks‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (opens new window)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (opens new window)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Źródło‎: Br J Haematol 2019;184(2):134-60.

Indeks‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (opens new window)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (opens new window)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Źródło‎: Support Care Cancer 2012;20(1):159-65.

Indeks‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (opens new window)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (opens new window)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Źródło‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeks‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (opens new window)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (opens new window)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Źródło‎: Oncologist 2010;15(9):935-43.

Indeks‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (opens new window)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (opens new window)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Źródło‎: Lung Cancer 2012;76(3):478-85.

Indeks‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (opens new window)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (opens new window)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Źródło‎: Eur J Haematol 2016;97(1):33-8.

Indeks‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (opens new window)

Dożylne podawanie żelaza

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (opens new window)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Źródło‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (opens new window)

Intravenous iron in oncology. (opens new window)

Auerbach M, Ballard H.

Źródło‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indeks‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (opens new window)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (opens new window)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Źródło‎: Int J Colorectal Dis 2016;31(3):543-51.

Indeks‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (opens new window)

How I treat cancer-associated anemia. (opens new window)

Gilreath JA, Rodgers GM

Źródło‎: Blood 2020;136(7):801-13.

Indeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (opens new window)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (opens new window)

Gilreath JA, Stenehjem DD, Rodgers GM.

Źródło‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Indeks‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (opens new window)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (opens new window)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Źródło‎: Eur J Haematol. 2023 110(4):354-61.

Indeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (opens new window)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (opens new window)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Źródło‎: Curr Oncol. 2023 24;30(9):7836-51.

Indeks‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (opens new window)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (opens new window)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Źródło‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indeks‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (opens new window)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (opens new window)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Źródło‎: World J Gastroenterol 2014;20(8):1972-85.

Indeks‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (opens new window)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (opens new window)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Źródło‎: South Asian J Cancer. 2023 15;12(2):93-9.

Indeks‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (opens new window)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (opens new window)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Źródło‎: J Clin Oncol 2008;26(10):1619-25.

Indeks‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (opens new window)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (opens new window)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Źródło‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indeks‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (opens new window)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (opens new window)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Źródło‎: Ann Oncol 2013;24(2):475-82.

Indeks‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (opens new window)

ONKOLOGIA
Leczenie niedokrwistości
polski
Leczenie niedokrwistości
https://assetsnffrgf-a.akamaihd.net/assets/ct/5a91b826b0/images/syn_placeholder_sqr.png

Kontakt z lokalnym przedstawicielem Komitetu Łączności ze Szpitalami

Bezpłatna, ogólnoświatowa pomoc dostępna 24 godziny na dobę dla lekarzy opiekujących się Świadkami Jehowy.

Kontakt

Informacje medyczne — pakiety

Uwzględnione tematy: Kliniczne strategie postępowania bez transfuzji w krwotoku i niedokrwistości, religijne i etyczne stanowisko Świadków Jehowy w sprawie leczenia oraz usługi świadczone środowisku medycznemu przy pomocy ogólnoświatowej sieci Komitetów Łączności ze Szpitalami.

Materiały do pobrania

Materiały wideo

Możliwości leczenia oraz czynniki medyczne i etyczne dla lekarzy, którzy leczą Świadków Jehowy.

Zobacz